Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates
暂无分享,去创建一个
J. Cooper | P. Feustel | A. Gianoukakis | M. Karam | A. Cheema | E. S. Postal | Paul J. Feustel | Postal Es
[1] H. Creutzig. High or low dose radioiodine ablation of thyroid remnants? , 2004, European Journal of Nuclear Medicine.
[2] Eva Forssell-Aronsson,et al. Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] W. Brenner. Is thyroid stunning a real phenomenon or just fiction? , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] M. Dempsey,et al. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[5] S. Ilgan,et al. Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma , 2001, Nuclear medicine communications.
[6] G. Braunstein,et al. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. , 2001, The Journal of clinical endocrinology and metabolism.
[7] S. Naddaf,et al. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[8] A. Alavi,et al. Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer , 2001, Clinical nuclear medicine.
[9] M. Bajén,et al. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] J. Hurley,et al. Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[11] R. O'mara,et al. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] B. de Keizer,et al. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy , 2000, Nuclear medicine communications.
[13] S. Doi,et al. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer , 2000, Clinical endocrinology.
[14] J. Humm,et al. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] S. Bae,et al. Comparison of Diagnostic and Post-therapy Radioiodine Scan in Well-Differentiated Thyroid Cancer and the Clinical Outcome , 2000 .
[16] K. Spicer,et al. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. , 1999, Journal of nuclear medicine technology.
[17] E. Mazzaferri. An overview of the management of papillary and follicular thyroid carcinoma. , 1999, Thyroid : official journal of the American Thyroid Association.
[18] L. Wartofsky. Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma , 1998 .
[19] J. Muratet,et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] R. Tsang,et al. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] P. Kao,et al. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. , 1998, The British journal of radiology.
[22] J. Clerc,et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma , 1998, European Journal of Nuclear Medicine.
[23] J. D. Lin,et al. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. , 1998, American journal of clinical oncology.
[24] M. Schlumberger,et al. THERAPEUTIC CONTROVERSY The Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer , 1998 .
[25] P. Giraud,et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] I. Mcdougall,et al. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. , 1997, Nuclear medicine communications.
[27] C. Bal,et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.
[28] I. Mcdougall,et al. What is the role of 1100 MBq (< 30 mCi) radioiodine 131I in the treatment of patients with differentiated thyroid cancer? , 1996, Nuclear medicine communications.
[29] C. Bal,et al. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. , 1996, Cancer.
[30] A. Samuel,et al. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] R. Tsang,et al. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. , 1994, The British journal of radiology.
[32] N. Katoh,et al. Iodine-131 treatment of thyroid cancer: relation between effective half-life and efficacy of treatment. , 1994, Radiation medicine.
[33] E. S. Pedro,et al. Influence of various scanning doses on subsequent I-131 ablation of thyroid remnants , 1994 .
[34] H. Park,et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. , 1994, Thyroid : official journal of the American Thyroid Association.
[35] Chen Wl,et al. Radioiodine I-131 therapy in the management of differentiated thyroid carcinoma: a review of 202 patients. , 1993 .
[36] W. Huang,et al. Radioiodine I-131 therapy in the management of differentiated thyroid carcinoma: a review of 202 patients. , 1993, Journal of the Formosan Medical Association = Taiwan yi zhi.
[37] K. Johansen,et al. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] M. Schlumberger,et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] L. Woolner,et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. , 1986, Mayo Clinic proceedings.
[40] R. Lloyd,et al. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] H. Blattmann,et al. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy]. , 1984, Nuklearmedizin. Nuclear medicine.
[42] G. Guiraudon,et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment , 1984, Cancer.
[43] C. Kuni,et al. Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer. , 1980, Radiology.
[44] W. Blahd,et al. Radioiodine I‐131 therapy in the management of thyroid cancer. A prospective study , 1977 .